Figure 2From: Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]Patient accounting. †Number represents any patient who discontinued during the active comparator controlled period. Percent is calculated using the number of patients that entered the first extension as the denominator. ‡ Other Reasons include lost to follow-up, patient moved, patient withdrew consent, or protocol deviation.Back to article page